Ignite Creation Date:
2025-12-24 @ 5:49 PM
Ignite Modification Date:
2026-03-01 @ 4:46 PM
Study NCT ID:
NCT03724968
Status:
TERMINATED
Last Update Posted:
2021-04-20
First Post:
2018-10-26
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
Sponsor:
Elizabeth Davis
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
VICC MEL 18114
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |